Wednesday, March 23, 2022
Zacks Research Daily features top research results from our team of analysts. Today’s Research Daily features new research reports on 16 major stocks, including Comcast Corp. (CMCSA), Danaher Corp. (DHR) and Amgen Inc. (AMGN). These research reports have been handpicked from the approximately 70 reports published today by our team of analysts.
You can see all today’s research reports here >>>
Comcast shares were down -6.1% year-to-date against Zacks’ cable TV industry decline of -7.3%. The Zacks analyst believes Comcast is constantly suffering from video subscriber attrition due to the cord cut. Additionally, a leveraged balance sheet is a major concern.
However, Comcast is also benefiting from the strength of the broadband subscriber base and strong momentum in the wireless industry. Its strategy to provide high-speed Internet access at an affordable price plays a central role in providing connectivity, improving earnings and customer experience.
Media consumption and waves of work-from-home and online learning bode well for Comcast’s internet business due to the recent pandemic. The company’s Peacock streaming service has grown in popularity in a short time and is a key catalyst in boosting broadband sales.
(You can read the full Comcast research report here >>>)
Shares of Danaher have outperformed the Zacks Diversified Operations sector over the past year (+33.9% vs -3.4%). The Zacks analyst believes the company is poised to benefit from Danaher Business System (“DBS”), healthy shareholder rewards, buyout benefits and product innovation in the quarters ahead. In the fourth quarter of 2021, its earnings and sales exceeded estimates by 7.6% and 4.38%, respectively.
Company expects year-over-year core revenue growth of 10% for the first quarter of 2022 and mid-single digits for 2022. Impact of COVID-related testing expected to drive sales to lower single digits single digits in the first quarter. However, cost inflation and issues related to supply chain restrictions could be a concern in the coming quarters. High debts could inflate financial obligations and forex woes could be cause for concern.
(You can read the full Danaher research report here >>>)
Shares of Amgen outperformed the Zacks Medical – Biomedical and Genetics sector over the period since the beginning of the year (+5.1% against -12.3%). The Zacks analyst believes Amgen is rapidly advancing its strong pipeline of early-stage and late-stage assets. Multiple Phase III readouts are expected in 2022. Lumakras, a first-in-class lung cancer treatment, is off to a strong start as its label expansion studies progress rapidly. Amgen also has a strong biosimilars pipeline, which is an important driver of long-term growth.
While key drugs like Prolia, Repatha, Xgeva and biosimilars are driving sales, growing competition for its legacy products is also hurting. However, pricing and competitive pressure impact many Amgen products and franchises. Several of the drugs marketed by Amgen are facing headwinds from rising prices and continued headwinds from COVID-19.
(You can read the full research report on Amgen here >>>)
Other noteworthy reports we feature today include Chevron Corporation (CVX), The Boeing Company (BA) and Canadian Pacific Railway Limited (CP).
Note: Sheraz Mian leads the equity research department at Zacks and is a well-known expert on overall earnings. He is frequently quoted in the written and electronic press and publishes the weekly Earnings Trends and Revenue overview reports. If you would like to receive an email notification whenever Sheraz publishes a new article, please click here>>>
To read today
Broadband subscriber gain boosts Comcast’s outlook (CMCSA)
Life Sciences Business Drives Danaher (DHR), High Costs
Amgen (AMGN) is rapidly advancing pipeline development
Aid to Boeing (BA) military companies, supply chain problem
According to the Zacks analyst, Boeing has a $2.6 trillion market opportunity for defense and space, which would bolster its growth. Still, COVID-induced supply chain shortages could hurt the stock’s results.
Moderna (MRNA) rides high on coronavirus vaccine success
According to the Zacks analyst, Moderna’s COVID-19 vaccine and booster are approved for emergency use in multiple countries, generating revenue.
Dividends boost Canadian Pacific (CP) despite labor issues
The Zacks analyst praises the company’s efforts to pay dividends to its shareholders, even in these difficult times. However, current labor issues are of great concern.
Customer Expansion, Strong Execution Aid Splunk (SPLK)
According to the Zacks analyst, Splunk enjoys strong execution across its platform, observability, and security businesses as organizations partner with it to secure their business infrastructure.
Organic growth supports Carlyle (CG), driving up costs
According to the Zacks analyst, the increase in Carlyle’s AUM balance and fund management fees is supporting its organic growth. Still, soaring costs and growing competition for investment opportunities are of concern.
IDEXX (IDXX) Benefits from Strong CAG Arm Growth Amid Forex Woes
The Zacks analyst is impressed with IDEXX’s strong gains in CAG revenue, led by double-digit gains in the US and international markets. Yet currency issues remain a concern.
The Estee Lauder Companies (EL) wins in the skincare category
According to the Zacks analyst, The Estee Lauder Companies has enjoyed strong skincare sales for some time. The category’s sales increased 12% year-over-year in the second quarter of fiscal 2022.
Chevron (CVX) strengthens Permian position with Noble Buy
The Zacks analyst believes Chevron’s takeover of Noble Energy has expanded its footprint in the lucrative Permian Basin, as well as adding cash-generating offshore assets in Israel.
Marriott (MAR) is likely to benefit from its robust expansion efforts
According to the Zacks analyst, Marriott continues to focus on expanding its portfolio of luxury and lifestyle brands to drive growth. This, combined with the pick-up in transient business and group demand, bodes well.
Buyouts and Digitization Efforts Perspectives from Aid Group 1 (GPI)
The Zacks analyst believes the Prime Automotive and Robinson Group takeovers will help Group 1 revenue. The company’s e-commerce efforts are also driving revenue growth.
Weather Variations and Third Party Ail Clearway (CWEN) Failure
According to the Zacks analyst, adverse weather conditions are reducing Clearway Energy’s (CWEN) generation from renewables and a third-party transmission line failure may disrupt scheduled delivery, reducing profitability.
Rising spending, growing competition Garlic MercadoLibre (MELI)
According to the Zacks analyst, MercadoLibre is hurt by rising spending on warehousing, free shipping subsidies and mPOS discounts. In addition, increased competition in e-commerce poses risks.
Forex Volatility, High Cost Reinsurance Group (RGA)
According to the Zacks analyst, increased expenses due to increased claims, credited interest and operating costs continue to affect revenue. The fluctuation of the Forex increases the financial risk.
Investor Alert: Legal Marijuana Looking for Big Gains?
Now is the time to get started in a young industry poised to skyrocket from $13.5 billion in 2021 to an expected $70.6 billion by 2028.
After a clean sweep of 6 election referendums in 5 states, pot is now legal in 36 states and DC federal legalization is expected soon and this could trigger an even bigger boon for investors. Zacks Investment Research recently closed pot stocks which climbed as high as +147.0%.
You are urged to consult Zacks’ immediately. Moneymakers Marijuana: An Investor’s Guide. It presents a timely watchlist of pot stocks and ETFs with exceptional growth potential.
Download Marijuana Moneymakers for FREE today >>
Click to get this free report
The Boeing Company (BA): Free Inventory Analysis Report
Chevron Corporation (CVX): Free Stock Analysis Report
Comcast Corporation (CMCSA): Free Stock Analysis Report
Amgen Inc. (AMGN): Free Stock Analysis Report
Danaher Corporation (DHR): Free Stock Analysis Report
Canadian Pacific Railway Limited (CP): Free Inventory Analysis Report
To read this article on Zacks.com, click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.